BiRd vs. Rd as Initial Therapy in Multiple Myeloma

PHASE3TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

June 22, 2022

Study Completion Date

July 22, 2022

Conditions
Multiple Myeloma
Interventions
DRUG

Clarithromycin

500mg PO twice daily on days 1-28 for a 28-day cycle.

DRUG

Lenalidomide

25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle

DRUG

Dexamethasone

20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger.

Trial Locations (2)

10065

Weill Cornell Medical College, New York

80045

University of Colorado - Anschutz Cancer Center, Aurora

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER